Validation of a <scp>SARS‐CoV‐2 RNA RT‐PCR</scp> assay for high‐throughput testing in blood of <scp>COVID</scp>‐19 convalescent plasma donors and patients

Strasser, Erwin; Steininger, Philipp; Korn, Klaus; Achenbach, Susanne; Tenbusch, Matthias; Cunningham, Sarah; Zimmermann, Robert A.; Überla, Klaus; Hackstein, Holger

doi:10.1111/trf.16178

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With clinical COVID-19, there have been a number of publications on viral RNA in the blood with the first publication using data from the early 2020 Wuhan outbreak. 81,82 Since then, more extensive publications from Spain, 83,84 Germany, 85,86 United States [87][88][89] and Norway 90 have been published using outpatients, hospital ward patients and critically ill patients. The positive detection rate is between 28% and 32% of hospitalized patients; however, those in intensive care have rates up to 78%.…”

Section: Dissemination and Transmission Viraemiamentioning

confidence: 99%

Pathophysiology of infection with SARS‐CoV‐2—What is known and what remains a mystery

Sridhar

Nicholls

2021

Respirology

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused extensive disruption and mortality since its recent emergence. Concomitantly, there has been a race to understand the virus and its pathophysiology. The clinical manifestations of COVID-19 are manifold and not restricted to the respiratory tract. Extrapulmonary manifestations involving the gastrointestinal tract, hepatobiliary system, cardiovascular and renal systems have been widely reported. However, the pathophysiology of many of these manifestations is controversial with questionable support for direct viral invasion and an abundance of alternative explanations such as pre-existing medical conditions and critical illness. Prior research on SARS-Co-V and NL63 was rapidly leveraged to identify angiotensin-converting enzyme 2 (ACE2) receptor as the key cell surface receptor for SARS-CoV-2. The distribution of ACE2 has been used as a starting point for estimating vulnerability of various tissue types to SARS-CoV-2 infection. Sophisticated organoid and animal models have been used to demonstrate such infectivity of extrapulmonary tissues in vitro, but the clinical relevance of these findings remains uncertain. Clinical autopsy studies are typically small and inevitably biased towards patients with severe COVID-19 and prolonged hospitalization. Technical issues such as delay between time of death and autopsy, use of inappropriate antibodies for paraffin-embedded tissue sections and misinterpretation of cellular structures as virus particles on electron micrograph images are additional problems encountered in the extant literature. Given that SARS-CoV-2 is likely to circulate permanently in human populations, there is no doubt that further work is required to clarify the pathobiology of COVID-19.

show abstract

Section: Dissemination and Transmission Viraemiamentioning

confidence: 99%

Pathophysiology of infection with SARS‐CoV‐2—What is known and what remains a mystery

Sridhar

Nicholls

2021

Respirology

View full text Add to dashboard Cite

show abstract

“…RT-PCR has limited resources, it has high specificity and high sensitivity [5]. However, according to the study of validation of the SARS-CoV-2 RT-PCR test [6], blood or hematological parameters showed high sensitivity and specificity as well as intra and inter-test precision and efficiency.…”

Section: Introduction Coronavirus 19 (Covid-19mentioning

confidence: 99%

Light Gradient Boosting with Hyper Parameter Tuning Optimization for COVID-19 Prediction

Ernawan¹,

Handayani²,

Fakhreldin³

et al. 2022

IJACSA

View full text Add to dashboard Cite

The 2019 coronavirus disease (COVID-19) caused pandemic and a huge number of deaths in the world. COVID-19 screening is needed to identify suspected positive COVID-19 or not and it can reduce the spread of COVID-19. The polymerase chain reaction (PCR) test for COVID-19 is a test that analyzes the respiratory specimen. The blood test also can be used to show people who have been infected with SARS-CoV-2. In addition, age parameters also contribute to the susceptibility of COVID-19 transmission. This paper presents the extra trees classification with random over-sampling by considering blood and age parameters for COVID-19 screening. This research proposes enhanced preprocessing data by using KNN Imputer to handle large missing values. The experiments evaluated the existing classification methods such as Random Forest, Extra Trees, Ada Boost, Gradient Boosting, and the proposed Light Gradient Boosting with hyperparameter tuning to measure the predictions of patients infected with SARS-CoV-2. The experiments used Albert Einstein Hospital test data in Brazil that consisted of 5,644 sample data from 559 patients with infected SARS-CoV-2. The experimental results show that the proposed scheme achieves an accuracy of about 98,58%, recall of 98,58%, the precision of 98,61%, F1-Score of 98,61%, and AUC of 0,9682.

show abstract

Prevalence and clinical relevance of viraemia in viral respiratory tract infections: a systematic review

Hagman,

Postigo,

Diez-Castro

et al. 2024

The Lancet Microbe

View full text Add to dashboard Cite

Validation of a SARS‐CoV‐2 RNA RT‐PCR assay for high‐throughput testing in blood of COVID‐19 convalescent plasma donors and patients

Cited by 4 publications

References 17 publications

Pathophysiology of infection with SARS‐CoV‐2—What is known and what remains a mystery

Pathophysiology of infection with SARS‐CoV‐2—What is known and what remains a mystery

Light Gradient Boosting with Hyper Parameter Tuning Optimization for COVID-19 Prediction

Prevalence and clinical relevance of viraemia in viral respiratory tract infections: a systematic review

Contact Info

Product

Resources

About